Differential sensitivity of mouse MLL-AF9 AML cells and normal BM cells to Jmjd1c KD. (A) Competitive proliferation assay of MLL-AF9 cells transduced with shRNAs targeting Jmjd1c-867 and Jmjd1c-868 or with a nontargeting control (Scr). Graph shows percentage of pMLS-GFP–transduced cells normalized to the percentage observed at day 0 (2 days after transduction). (B) Competitive proliferation assay of c-Kit–enriched BM cells transduced with shRNAs targeting Jmjd1c-867 and Jmjd1c-868 or with a nontargeting control (Scr). Graph shows percentage of pMLS-GFP–transduced cells normalized to day 0 (2 days after transduction). (C) Relative expression of Jmjd1c in MLL-AF9 cells transduced with Scr or Jmjd1c-targeting shRNAs at day 2 after transduction. (D) Relative expression of Jmjd1c in c-Kit⁺ cells transduced with Scr or Jmjd1c-targeting shRNAs at day 2 after transduction. (E) Relative Jmjd1c mRNA expression in c-Kit⁺ mouse BM cells and in MLL-AF9 primary mouse leukemic cells. (F) Number of colonies generated by MLL-AF9 cells transduced by pMLS-Scr, pMLS-867, or pMLS-868. Cells were plated in semisolid media 2 days after transduction. Error bars indicate standard deviation of the mean (n = 3). (G) Number of colonies generated by c-Kit⁺ cells transduced by pMLS-Scr, pMLS-867, or pMLS-868. Cells were plated in semisolid media 2 days after transduction. Error bars indicate standard deviation of the mean (n = 3). (H) Survival curves of sublethally irradiated mice transplanted with 10⁴ MLL-AF9 cells transduced with pMLS-Scr, pMLS-867, or pMLS-868. GFP+ cells were sorted by FACS and transplanted 2 days after transduction.